Isomorphic Labs, a spin-off of Google DeepMind and a subsidiary of Alphabet (NASDAQ:GOOGL) has planned to start clinical trials for AI-designed drugs by the end of this year, according to CEO ...

In 2021, the company spun out Isomorphic Labs, an AI drug discovery company. But Isomorphic’s initial focus is on small-molecule drug discovery, with protein-based drugs remaining a distant ...

Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma partnerships with Eli ...

“At the same time, I saw that with the launch of Isomorphic Labs, and their plans based on AlphaFold2, that they were starting many things at once. I felt like the opportunity was really in ...

Isomorphic Labs launches into an already well-populated drug discovery category, with many large drugmakers exploring the technology along with a host of specialist players like Exscientia ...

DeepMind’s new AlphaFold 3 expands to DNA, RNA modeling Google DeepMind expands its AlphaFold AI system to model how proteins interact with other cell structures including DNA and RNA.

Radical Ventures partner, Aaron Rosenberg, the former Head of Strategy & Operations at DeepMind, where he contributed to spinning out Isomorphic Labs to build upon AlphaFold, said: “We’ve ...

Around this time, DeepMind also spawned a sister company in the form of Isomorphic Labs, which is focused on applying DeepMind’s AI research to transform drug discovery. It was a combination of ...